Character Biosciences has secured $93 million in Series B funding to support two lead programmes aimed at treating age-related macular degeneration, a major cause of vision loss for people over 60. The firm uses artificial intelligence to maximise clinical trial data’s value and will start phase 1 testing for both programmes later this year.
Google Suspends Account of Advertiser That Distributed Malware
Google suspended the account of an advertiser who was using sponsored ads to deliver malware, instead of the promised access to DeepSeek. The malicious ads
